Table 2 Baseline assessment
 • Review of inclusion and exclusion criteria | |
 • Medical and medication history, physical examination including height, weight, vital signs (blood pressure, heart rate, respiratory rate, body temperature), oxygen saturation, ECOG-performance status | |
 • Laboratory Tests: | |
  o Hematology panel: hemoglobin, platelets, white blood cell (WBC) count and WBC differential (neutrophils, lymphocytes) | |
  o Chemistry panel: sodium, potassium, calcium, magnesium, creatinine, urea, total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, albumin, LDH, glucose, amylase, lipase | |
  o Free T3/T4 and TSH | |
  o Coagulation: INR, aPTT | |
  o CA 72–4 (CEA, CA 19–9 optional) | |
  o Hepatitis B/C screening test (HBsAg, anti-HBc, anti-HBs, anti-HCV) | |
  o HIV screening test (HIV 1/2 antigen/antibody test) | |
  o Pregnancy test for women of childbearing potential within 24 h prior to start of the treatment | |
 • Blood draw for translational research | |
 • Obtain paraffin-embedded tumor-tissue for translational research | |
 • Echocardiography and ECG | |
 • Quality of life assessment (EORTC QLQ-C30 and STO-22) | |
 • Disease assessment by radiological imaging of the chest, abdomen, pelvis and all other sites of disease (CT/MRI-scan) |